RGNCY-0107 (PDZ1i MDA-9/Syntenin PDZ1 inhibitor)
PDZ1i is a targeted inhibitor of MDA-9/Syntenin PDZ1 domain which is a potential molecular target for prostate cancer. By interacting with IGF-1, MDA-9/Syntenin activates STAT3 and regulates prostate cancer pathogenesis. PDZ1i is well tolerated in vivo with a significant half life of 9h. PDZ1i blocks prostate cancer cell in and migration in vitro and metastasis in vivo in immunocompetent mice. Therefore, PDZ1i demonstrates potential as a therapy for prostate cancer, and possibly other cancers that express elevated MDA-9/Syntenin levels.
Systematic Name: N-(2,5-dimethyl-4-(3-(5-phenyl-1,3,4-oxadiazol-2-yl)propanamido)phenyl)-8-oxo-5,6,7,8-tetrahydro-4H-cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide
Mol Wt: 538.57
Tags: Small molecules, Cancer, migration, Prostate, Invasion, metastasis, RGNCY-0107, PDZ1i, prostate cancer, STAT3, IGF-1